Liraglutide May Blunt Impact of Exercise in Dysregulated T2DM

Share this content:
Liraglutide May Blunt Impact of Exercise in Dysregulated T2DM
Liraglutide May Blunt Impact of Exercise in Dysregulated T2DM

THURSDAY, Feb. 16, 2017 (HealthDay News) -- For individuals with dysregulated type 2 diabetes, the addition of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide may attenuate the impact of exercise, according to a study published online Feb. 11 in Diabetes, Obesity and Metabolism.

Peter G. Jørgensen, from the University of Copenhagen in Denmark, and colleagues examined cardiac function before and after 16 weeks of GLP-1RA liraglutide treatment or placebo combined with supervised exercise among 33 dysregulated patients with type 2 diabetes treated with diet and/or metformin.

The researchers found that early diastolic myocardial tissue velocity improved with exercise in the placebo group (−7.1 ± 1.6 to −7.7 ± 1.8 cm/s; P = 0.01), but no improvement was seen in the liraglutide group (−7.1 ± 1.4 to −7.0 ± 1.4 cm/s; P = 0.60) (between-group difference, P = 0.02). There was improvement in the ratio of early and atrial mitral annular tissue velocities in the placebo group (1.0 ± 0.4 to 1.2 ± 0.4; P = 0.003), but no improvement in the liraglutide group (1.0 ± 0.3 to 1.0 ± 0.3; P = 0.87) (between-group difference, P = 0.03). Heart rate and left ventricular structure or function did not differ significantly within or between the groups.

"Addition of liraglutide to exercise in sedentary patients with dysregulated type 2 diabetes may blunt the suggested beneficial effect of exercise on left ventricular diastolic function," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, which funded the study and sponsored the liraglutide and placebo pens.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »